Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director | September 30, 2026 | October 03, 2026 |
| GE HealthCare Technologies Inc.GEHC · Entity 1711 | Director · President and CEO | September 03, 2026 | September 04, 2026 |
| GENERAL ELECTRIC COGE · Entity 2813 | Senior Vice President | March 01, 2022 | March 04, 2022 |
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | Director · President & CEO | September 02, 2021 | September 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 74,077.176 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 560.897 · Balance 74,077.176 F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
GE HealthCare Technologies Inc.
Report date September 03, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 241,606 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Tax withholding · Disposed 6,303 · Balance 241,606 F1: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
GENERAL ELECTRIC CO
Report date March 01, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,443 |
Reported balance
After 2022-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 14,443 · Balance 14,443 F1: 1 for 1 F2: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $92.23 · Expires 2032-03-01 | Direct | 63,044 |
Reported balance
After 2022-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-01 · Grant · Acquired 63,044 · Balance 63,044 F2: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date |
Filing footnotes · ownership attribution and instrument terms
F1: 1 for 1
F2: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date September 02, 2021 · Filed September 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,713 |
Ending reported balance
After 2021-09-03 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-09-02 · Exercise / conversion · Acquired 71,829 · Balance 288,542 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Row 2 · 2021-09-02 · Sale · Disposed 71,829 · Balance 216,713 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.34 to $76.465 per share of common stock. Row 3 · 2021-09-03 · Exercise / conversion · Acquired 46,605 · Balance 263,318 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Row 4 · 2021-09-03 · Sale · Disposed 46,605 · Balance 216,713 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.40 to $76.09 per share of common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.88 · Expires 2022-03-06 | Direct | 46,605 |
Reported balance
After 2021-09-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-09-02 · Exercise / conversion · Disposed 71,829 · Balance 46,605 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date. F5: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015. F6: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.88 · Expires 2022-03-06 | Direct | 0 |
Reported balance
After 2021-09-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-09-03 · Exercise / conversion · Disposed 46,605 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date. F5: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015. F6: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
F2: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.34 to $76.465 per share of common stock.
F3: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.40 to $76.09 per share of common stock.
F4: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date.
F5: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015.
F6: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2018 Filed Mar 27, 2018 21:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 10,994 | $54.15 | $595,325.10 |
DisclosureSEC source: 0001209191-18-021783 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,768 Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 343 | $54.15 | $18,573.45 |
DisclosureSEC source: 0001209191-18-021783 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,762 Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 343 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021783 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units/Contract Stock · Derivative | 368 | $56.14 Strike: $0.00 | $20,659.52 |
DisclosureSEC source: 0001209191-18-019823 · doc4.xml · derivative · entry 10 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,619 Underlying: Common Stock · 368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/14/16 of which the second installment vested on 3/14/18 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F4 · derivative.exercise_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/14/16 of which the second installment vested on 3/14/18 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F4 · derivative.expiration_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/14/16 of which the second installment vested on 3/14/18 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 368 | $56.14 | $20,659.52 |
DisclosureSEC source: 0001209191-18-019823 · doc4.xml · nonDerivative · entry 6 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,762 Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 368 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019823 · doc4.xml · nonDerivative · entry 5 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 14,842 | $56.14 | $833,229.88 |
DisclosureSEC source: 0001209191-18-019823 · doc4.xml · nonDerivative · entry 4 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,762 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units/Contract Stock · Derivative | 290 | $56.23 Strike: $0.00 | $16,306.70 |
DisclosureSEC source: 0001209191-18-019823 · doc4.xml · derivative · entry 9 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,987 Underlying: Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/17 of which the first installment vested on 3/13/18 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F3 · derivative.exercise_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/17 of which the first installment vested on 3/13/18 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F3 · derivative.expiration_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/17 of which the first installment vested on 3/13/18 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantRestricted Stock Units/Contract Stock · Derivative | 19,385 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019823 · doc4.xml · derivative · entry 8 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,277 Underlying: Common Stock · 19,385 shares Expires not disclosed F2 · derivative.exercise_price: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2018 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F2 · derivative.exercise_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2018 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F2 · derivative.expiration_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2018 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 75,069 | $0.00 Strike: $56.23 | $0.00 |
DisclosureSEC source: 0001209191-18-019823 · doc4.xml · derivative · entry 7 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,069 Underlying: Common Stock · 75,069 shares Expires 2026-03-13 F1 · derivative.exercise_date: The grant will vest as to one-third of the shares on the first anniversary of the grant date of 3/13/2018 and thereafter in monthly installments through the following twenty-four months. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 290 | $56.23 | $16,306.70 |
DisclosureSEC source: 0001209191-18-019823 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,604 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019823 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 11,687 | $56.23 | $657,160.01 |
DisclosureSEC source: 0001209191-18-019823 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,604 Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:24 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 26,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011337 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,291 F3 · shares: On February 15, 2018, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2017, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 33% of the shares will vest on March 13, 2018 at 150% target, the first anniversary of the grant date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:24 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 34,182 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011337 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,377 F2 · shares: On February 15, 2018, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2017, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2018 at 150% target, the second anniversary of the grant date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:24 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 25,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011337 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,195 F1 · shares: On February 15, 2018, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2017, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 34% of the shares will vest on March 23, 2018, the third anniversary of the grant date. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 2,945.86 | $62.80 | $185,000.01 |
DisclosureSEC source: 0000014272-18-000047 · wf-form4_151787285194313.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,412.747 Underlying: Common Stock, $0.10 par value · 2,945.86 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 23:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 530.352 | $61.28 | $32,499.97 |
DisclosureSEC source: 0000014272-18-000014 · wf-form4_151502231543091.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,406.97 Underlying: Common Stock, $0.10 par value · 530.352 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 20:49 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 509.884 | $63.74 | $32,500.01 |
DisclosureSEC source: 0000014272-17-000182 · wf-form4_150706374464691.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,821.273 Underlying: Common Stock, $0.10 par value · 509.884 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 22:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 560.348 | $55.72 | $31,222.59 |
DisclosureSEC source: 0000014272-17-000152 · wf-form4_149929203153684.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,253.992 Underlying: Common Stock, $0.10 par value · 560.348 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 23:19 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 528.687 | $54.38 | $28,750.00 |
DisclosureSEC source: 0000014272-17-000116 · wf-form4_149134795875582.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,640.725 Underlying: Common Stock, $0.10 par value · 528.687 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 24, 2017 Filed Mar 27, 2017 23:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units/Contract Stock · Derivative | 413 | $42.74 Strike: $0.00 | $17,651.62 |
DisclosureSEC source: 0001209191-17-023004 · doc4.xml · derivative · entry 8 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,892 Underlying: Common stock · 413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/24/14 of which the third installment vested on 3/24/17 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F2 · derivative.exercise_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/24/14 of which the third installment vested on 3/24/17 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F2 · derivative.expiration_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/24/14 of which the third installment vested on 3/24/17 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 24, 2017 Filed Mar 27, 2017 23:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 413 | $42.74 | $17,651.62 |
DisclosureSEC source: 0001209191-17-023004 · doc4.xml · nonDerivative · entry 6 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,877 Read SEC document |
| March 24, 2017 Filed Mar 27, 2017 23:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 413 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-023004 · doc4.xml · nonDerivative · entry 5 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 24, 2017 Filed Mar 27, 2017 23:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 13,640 | $42.74 | $582,973.60 |
DisclosureSEC source: 0001209191-17-023004 · doc4.xml · nonDerivative · entry 4 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,877 Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 23:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units/Contract Stock · Derivative | 353 | $42.35 Strike: $0.00 | $14,949.55 |
DisclosureSEC source: 0001209191-17-023004 · doc4.xml · derivative · entry 7 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,305 Underlying: Common Stock · 353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/23/15 of which the second installment vested on 3/23/17 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F1 · derivative.exercise_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/23/15 of which the second installment vested on 3/23/17 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F1 · derivative.expiration_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/23/15 of which the second installment vested on 3/23/17 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 23:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 353 | $42.35 | $14,949.55 |
DisclosureSEC source: 0001209191-17-023004 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,517 Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 23:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 353 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-023004 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 23:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 11,308 | $42.35 | $478,893.80 |
DisclosureSEC source: 0001209191-17-023004 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,517 Read SEC document |
| March 14, 2017 Filed Mar 15, 2017 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units/Contract Stock · Derivative | 378 | $43.03 Strike: $0.00 | $16,265.34 |
DisclosureSEC source: 0001209191-17-020775 · doc4.xml · derivative · entry 6 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,658 Underlying: Common Stock · 378 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/14/16 of which the first installment vested on 3/14/17 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F3 · derivative.exercise_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/14/16 of which the first installment vested on 3/14/17 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F3 · derivative.expiration_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/14/16 of which the first installment vested on 3/14/17 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 14, 2017 Filed Mar 15, 2017 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 378 | $43.03 | $16,265.34 |
DisclosureSEC source: 0001209191-17-020775 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,825 Read SEC document |
| March 14, 2017 Filed Mar 15, 2017 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 378 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020775 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2017 Filed Mar 15, 2017 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 15,730 | $43.03 | $676,861.90 |
DisclosureSEC source: 0001209191-17-020775 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,825 Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantRestricted Stock Units/Contract Stock · Derivative | 21,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020775 · doc4.xml · derivative · entry 5 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,036 Underlying: Common Stock · 21,750 shares Expires not disclosed F2 · derivative.exercise_price: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2017 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F2 · derivative.exercise_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2017 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F2 · derivative.expiration_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2017 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 84,071 | $0.00 Strike: $43.68 | $0.00 |
DisclosureSEC source: 0001209191-17-020775 · doc4.xml · derivative · entry 4 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,071 Underlying: Common Stock · 84,071 shares Expires 2025-03-13 F1 · derivative.exercise_date: The grant will vest as to one-third of the shares on the first anniversary of the grant date of 3/13/2017 and thereafter in monthly installments through the following twenty-four months. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001209191-17-015845 · doc4.xml · derivative · entry 4 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,588 Underlying: Common Stock · 40,000 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-third of the stock options vested on the first anniversary of the grant date which is March 1, 2012 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the 3rd anniversary of the grant date. F5 · balance_after: This employee's stock option was previously reported as covering 215,794 shares of common stock at an exercise price of $27.78 per share. In accordance with the terms of the stock option plan, the exercise price of the option and number of shares subject to the option have been adjusted to reflect the two-for-one stock split that occurred on December 21, 2016. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 40,000 | $42.28 | $1,691,224.00 |
DisclosureSEC source: 0001209191-17-015845 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,555 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $41.88 to $42.53. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 40,000 | $13.89 | $555,600.00 |
DisclosureSEC source: 0001209191-17-015845 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 8,018 | $42.28 | $339,005.85 |
DisclosureSEC source: 0001209191-17-015845 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,555 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $41.88 to $42.53. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 21:44 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 34,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-012193 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,573 F4 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2017 at 150% target, the first anniversary of the grant date. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 21:44 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 24,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-012193 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,394 F3 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 33% of the shares will vest on March 23, 2017, the second anniversary of the grant date. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 21:44 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 29,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-012193 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,824 F1 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 24, 2014 Performance Stock Award. Accordingly, 34% of the shares will vest on March 24, 2017, the third anniversary of the grant date. F2 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date and one additional unit of unvested performance based restricted stock ("PSU") for each PSU owned as of that date, as reflected in the totals listed on this Form 4. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 22:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,448.975 | $49.29 | $169,999.98 |
DisclosureSEC source: 0000014272-17-000030 · wf-form4_148616025206853.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,112.038 Underlying: Common Stock, $0.10 par value · 3,448.975 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2016 Filed Jan 5, 2017 01:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 491.958 | $58.44 | $28,750.03 |
DisclosureSEC source: 0000014272-17-000011 · wf-form4_148357924667853.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,634.308 Underlying: Common Stock, $0.10 par value · 491.958 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| November 08, 2016 Filed Nov 9, 2016 21:16 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $27.78 | $0.00 |
DisclosureSEC source: 0001209191-16-149054 · doc4.xml · derivative · entry 4 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,794 Underlying: Common Stock · 20,000 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-third of the stock options vested on the first anniversary of the grant date which is March 1, 2012 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the 3rd anniversary of the grant date. Read SEC document |
| November 08, 2016 Filed Nov 9, 2016 21:16 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 20,000 | $80.02 | $1,600,302.00 |
DisclosureSEC source: 0001209191-16-149054 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,593 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $80.00 to $80.11. Read SEC document |
| November 08, 2016 Filed Nov 9, 2016 21:16 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 20,000 | $27.78 | $555,600.00 |
DisclosureSEC source: 0001209191-16-149054 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 21:16 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 4,009 | $77.00 | $308,707.83 |
DisclosureSEC source: 0001209191-16-149054 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,593 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $77.00 to $77.02. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 21:50 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 533.197 | $53.92 | $28,749.98 |
DisclosureSEC source: 0000014272-16-000479 · wf-form4_147561784446874.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,119.019 Underlying: Common Stock, $0.10 par value · 533.197 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2016 Filed Jul 5, 2016 22:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 372.962 | $73.55 | $27,431.36 |
DisclosureSEC source: 0000014272-16-000446 · wf-form4_146775946421886.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,572.989 Underlying: Common Stock, $0.10 par value · 372.962 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.